ID22812A - Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2 - Google Patents

Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2

Info

Publication number
ID22812A
ID22812A IDW990403D ID990403D ID22812A ID 22812 A ID22812 A ID 22812A ID W990403 D IDW990403 D ID W990403D ID 990403 D ID990403 D ID 990403D ID 22812 A ID22812 A ID 22812A
Authority
ID
Indonesia
Prior art keywords
imidazolinylaminoindol
adrenoseptor
alfa
agonists
compound
Prior art date
Application number
IDW990403D
Other languages
English (en)
Indonesian (id)
Inventor
Raymond Todd Henry
Russell James Sheldon
William Lee Seibel
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID22812A publication Critical patent/ID22812A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDW990403D 1996-11-25 1997-11-21 Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2 ID22812A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3177796P 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
ID22812A true ID22812A (id) 1999-12-09

Family

ID=21861336

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990403D ID22812A (id) 1996-11-25 1997-11-21 Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2

Country Status (23)

Country Link
US (2) US6162818A (fr)
EP (1) EP0944621B1 (fr)
JP (1) JP2001506981A (fr)
KR (1) KR100395356B1 (fr)
CN (1) CN1092652C (fr)
AR (1) AR013875A1 (fr)
AT (1) ATE275142T1 (fr)
AU (1) AU735767B2 (fr)
BR (1) BR9713542A (fr)
CA (1) CA2271841C (fr)
CO (1) CO4910149A1 (fr)
CZ (1) CZ180599A3 (fr)
DE (1) DE69730516T2 (fr)
ES (1) ES2225998T3 (fr)
HU (1) HUP9904215A3 (fr)
ID (1) ID22812A (fr)
IL (1) IL130024A (fr)
NO (1) NO992470L (fr)
PE (1) PE16299A1 (fr)
SK (1) SK68399A3 (fr)
TR (1) TR199901885T2 (fr)
WO (1) WO1998023610A1 (fr)
ZA (1) ZA9710577B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
EP1196380A2 (fr) * 1999-07-15 2002-04-17 NPS Allelix Corp. Composes heterocycliques destines au traitement de la migraine
WO2001040183A1 (fr) * 1999-12-03 2001-06-07 Alcon Universal Ltd. 1-aminoalkyl-1 h-indoles pour traiter le glaucome
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
JP4326468B2 (ja) * 2002-06-24 2009-09-09 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なインドール誘導体
DE60332769D1 (de) 2002-11-07 2010-07-08 Organon Nv Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
DK2320911T3 (da) * 2008-08-01 2014-11-03 Eye Therapies Llc Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (fr) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Dispositifs d'inhalation et procédés associés pour administration de composés hypnotiques sédatifs
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití

Also Published As

Publication number Publication date
KR20000069088A (ko) 2000-11-25
AU735767B2 (en) 2001-07-12
NO992470L (no) 1999-07-26
CA2271841C (fr) 2003-07-08
JP2001506981A (ja) 2001-05-29
CN1092652C (zh) 2002-10-16
DE69730516D1 (de) 2004-10-07
ZA9710577B (en) 1998-06-25
SK68399A3 (en) 2000-07-11
US6395764B1 (en) 2002-05-28
KR100395356B1 (ko) 2003-08-21
CN1238771A (zh) 1999-12-15
DE69730516T2 (de) 2005-09-01
AR013875A1 (es) 2001-01-31
IL130024A0 (en) 2000-02-29
ATE275142T1 (de) 2004-09-15
CO4910149A1 (es) 2000-04-24
TR199901885T2 (xx) 1999-10-21
US6162818A (en) 2000-12-19
IL130024A (en) 2002-12-01
CA2271841A1 (fr) 1998-06-04
EP0944621B1 (fr) 2004-09-01
HUP9904215A2 (hu) 2000-06-28
WO1998023610A1 (fr) 1998-06-04
ES2225998T3 (es) 2005-03-16
BR9713542A (pt) 2000-01-25
EP0944621A1 (fr) 1999-09-29
PE16299A1 (es) 1999-03-12
AU5438098A (en) 1998-06-22
CZ180599A3 (cs) 1999-11-17
NO992470D0 (no) 1999-05-21
HUP9904215A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
ID22812A (id) Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2
ID24836A (id) Agonis prostaglandin
ID17182A (id) Adrenergis b3 agonis pilihan
ID23857A (id) Senyawa-senyawa guanidinil heterosiklik yang berguna sebagai agonis adrenoceptor alfa-2
DE69733506D1 (de) Schmierende Zusammensetzung
DE69704549T2 (de) Aufnahmevorrichtung
DE69718508D1 (de) Antitraspirant zusammensetzung
DE69713026D1 (de) Positioniervorrichtung
DE59711798D1 (de) Gestrick
EE03832B1 (et) Heptapeptiidanaloogid
ATE277050T1 (de) Trizyclische vasopressin agoniste
DE69725647D1 (de) Kamerastruktur
NO984290D0 (no) Farmas°ytisk nyttige forbindelser
DK0839989T3 (da) Udløselig forbindelse
DE29617198U1 (de) Stativ
DE59810818D1 (de) Fügeverbindung
DE69708312D1 (de) Leerlauf-rolle
ID17561A (id) Komposisi untuk pemakaian luar
ID22060A (id) Senyawa-senyawa 2-imidazolinilaminobenzoksazol berguna sebagai agonis adrenoseptor
BR9711205A (pt) Composto
BR9707835A (pt) Composiç
DE29619780U1 (de) Entstörvorrichtung
BR9709815A (pt) Composicão
ID22676A (id) Senyawa-senyawa 2-imidalinilaminoindazol yang berguna sebagai agonis adrenoseptor alfa-2
ID23038A (id) Senyawa-senyawa guanidinilamino heterosiklus yang berguna sebagai agonis adrenoseptor alfa-2